Aimovig (CGRP monoclonal antibody) is approved by the FDA!

May 18, 2018

Yesterday the FDA approved the long-awaited breakthrough drug for the prevention of migraines. It promises to provide relief to two out of three migraine sufferers with minimal side effects.

It should become available in a couple of weeks. The cost of the monthly injection is $575, but hopefully most insurance plans will cover it. The insurance companies are likely to require that the patient first try and fail a couple of inexpensive drugs before paying for Aimovig, as they do with Botox.

The medicine comes in a simple-to-use auto-injector and after the initial injection patients will be able to self-administer it.

To patients of the New York Headache Center – please call the office and schedule an appointment.

Written by
Alexander Mauskop, MD
Continue reading
April 10, 2026
Research
Migraines often strike on one side. Scientists say that matters more than we think
Migraines often strike on one side. Scientists say that matters more than we think New data may improve outcomes when we use TMS to treat migraines
Read article
March 26, 2026
Alternative Therapies
Lidocaine-Based Treatments Offer Another Option for Severe Migraines
This post explains how lidocaine, beyond its traditional use as a local anesthetic, can be given by IV or directly into the middle meningeal artery to help break severe, treatment-resistant migraines, with early studies showing promising relief and generally mild, manageable side effects.
Read article